UA77950C2 - Use of mutants of cc chemokines for treatment of multiple sclerosis - Google Patents

Use of mutants of cc chemokines for treatment of multiple sclerosis Download PDF

Info

Publication number: UA77950C2
Authority: UA; Ukraine
Prior art keywords: mutant; chemokine; amino acids; mir; kamte5
Prior art date: 2000-10-04

Application number

UA2003044038A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-04

Filing date

2001-03-10

Publication date

2007-02-15

2001-03-10 Application filed by Applied Research Systems filed Critical Applied Research Systems

2007-02-15 Publication of UA77950C2 publication Critical patent/UA77950C2/uk

Links

201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 11
102000001902 CC Chemokines Human genes 0.000 title claims abstract description 10
108010040471 CC Chemokines Proteins 0.000 title claims abstract description 10
102000019034 Chemokines Human genes 0.000 claims abstract description 36
108010012236 Chemokines Proteins 0.000 claims abstract description 36
230000027455 binding Effects 0.000 claims abstract description 22
230000035772 mutation Effects 0.000 claims abstract description 11
208000016192 Demyelinating disease Diseases 0.000 claims abstract description 10
125000002091 cationic group Chemical group 0.000 claims abstract description 9
230000002829 reductive effect Effects 0.000 claims abstract description 6
235000001014 amino acid Nutrition 0.000 claims description 63
150000001413 amino acids Chemical group 0.000 claims description 52
108020004414 DNA Proteins 0.000 claims description 8
239000004480 active ingredient Substances 0.000 claims description 7
235000004279 alanine Nutrition 0.000 claims description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
108090000765 processed proteins & peptides Proteins 0.000 claims description 4
239000013598 vector Substances 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 2
101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 2
108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
229910052799 carbon Inorganic materials 0.000 claims description 2
AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 2
108091084679 miR-3 stem-loop Proteins 0.000 claims description 2
108091033354 miR-3-1 stem-loop Proteins 0.000 claims description 2
108091058771 miR-3-2 stem-loop Proteins 0.000 claims description 2
108091047102 miR-4 stem-loop Proteins 0.000 claims description 2
108091049748 miR-4-1 stem-loop Proteins 0.000 claims description 2
108091058497 miR-4-2 stem-loop Proteins 0.000 claims description 2
102000053602 DNA Human genes 0.000 claims 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
239000004471 Glycine Substances 0.000 claims 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 1
239000004473 Threonine Substances 0.000 claims 1
239000001963 growth medium Substances 0.000 claims 1
229920001184 polypeptide Polymers 0.000 claims 1
102000004196 processed proteins & peptides Human genes 0.000 claims 1
238000010188 recombinant method Methods 0.000 claims 1
210000004027 cell Anatomy 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 20
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 19
102000004169 proteins and genes Human genes 0.000 description 19
206010033799 Paralysis Diseases 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
229920000669 heparin Polymers 0.000 description 16
229960002897 heparin Drugs 0.000 description 16
125000003275 alpha amino acid group Chemical group 0.000 description 15
239000000243 solution Substances 0.000 description 13
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
201000010099 disease Diseases 0.000 description 12
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 11
238000004458 analytical method Methods 0.000 description 10
230000000694 effects Effects 0.000 description 10
230000003993 interaction Effects 0.000 description 10
210000001616 monocyte Anatomy 0.000 description 10
239000000872 buffer Substances 0.000 description 9
230000006041 cell recruitment Effects 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
102000005962 receptors Human genes 0.000 description 9
108020003175 receptors Proteins 0.000 description 9
239000012528 membrane Substances 0.000 description 8
239000007983 Tris buffer Substances 0.000 description 7
210000003141 lower extremity Anatomy 0.000 description 7
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
230000035605 chemotaxis Effects 0.000 description 6
238000004587 chromatography analysis Methods 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
102000008300 Mutant Proteins Human genes 0.000 description 5
108010021466 Mutant Proteins Proteins 0.000 description 5
210000001744 T-lymphocyte Anatomy 0.000 description 5
239000012148 binding buffer Substances 0.000 description 5
201000002491 encephalomyelitis Diseases 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000000034 method Methods 0.000 description 5
108091028606 miR-1 stem-loop Proteins 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000007115 recruitment Effects 0.000 description 5
208000031886 HIV Infections Diseases 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
230000009137 competitive binding Effects 0.000 description 4
230000003053 immunization Effects 0.000 description 4
238000002649 immunization Methods 0.000 description 4
231100000350 mutagenesis Toxicity 0.000 description 4
238000002703 mutagenesis Methods 0.000 description 4
239000013612 plasmid Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
229940071127 thioglycolate Drugs 0.000 description 4
CWERGRDVMFNCDR-UHFFFAOYSA-M thioglycolate(1-) Chemical compound [O-]C(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-M 0.000 description 4
208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 3
206010012305 Demyelination Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
229920002971 Heparan sulfate Polymers 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 3
108010081690 Pertussis Toxin Proteins 0.000 description 3
102000016611 Proteoglycans Human genes 0.000 description 3
108010067787 Proteoglycans Proteins 0.000 description 3
101100061516 Schizosaccharomyces pombe (strain 972 / ATCC 24843) csk1 gene Proteins 0.000 description 3
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000037396 body weight Effects 0.000 description 3
238000005277 cation exchange chromatography Methods 0.000 description 3
210000000170 cell membrane Anatomy 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 3
238000010828 elution Methods 0.000 description 3
208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
239000001632 sodium acetate Substances 0.000 description 3
235000017281 sodium acetate Nutrition 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000005406 washing Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
108091026890 Coding region Proteins 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
229920002683 Glycosaminoglycan Polymers 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
241001529936 Murinae Species 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
208000007536 Thrombosis Diseases 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
241000700605 Viruses Species 0.000 description 2
210000000683 abdominal cavity Anatomy 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
238000013459 approach Methods 0.000 description 2
210000003050 axon Anatomy 0.000 description 2
210000001638 cerebellum Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
230000003399 chemotactic effect Effects 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
210000003414 extremity Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
208000027866 inflammatory disease Diseases 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 2
238000002955 isolation Methods 0.000 description 2
230000003902 lesion Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
230000028550 monocyte chemotaxis Effects 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
239000008188 pellet Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
239000013641 positive control Substances 0.000 description 2
230000008092 positive effect Effects 0.000 description 2
238000000159 protein binding assay Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
210000000278 spinal cord Anatomy 0.000 description 2
238000011272 standard treatment Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
230000001629 suppression Effects 0.000 description 2
-1 1309 Proteins 0.000 description 1
GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
108050006947 CXC Chemokine Proteins 0.000 description 1
102000019388 CXC chemokine Human genes 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010053070 Glutathione Disulfide Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
101000920778 Homo sapiens DNA excision repair protein ERCC-8 Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
102000004890 Interleukin-8 Human genes 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
102000006386 Myelin Proteins Human genes 0.000 description 1
108010083674 Myelin Proteins Proteins 0.000 description 1
101150094382 NSS gene Proteins 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
101800001775 Nuclear inclusion protein A Proteins 0.000 description 1
241001494479 Pecora Species 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
230000009809 T cell chemotaxis Effects 0.000 description 1
206010046543 Urinary incontinence Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000556 agonist Substances 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000000137 annealing Methods 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
210000005056 cell body Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
230000031902 chemoattractant activity Effects 0.000 description 1
239000002559 chemokine receptor antagonist Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
238000012937 correction Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
210000004443 dendritic cell Anatomy 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000004520 electroporation Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000007396 fibrous gliosis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
238000005755 formation reaction Methods 0.000 description 1
239000012634 fragment Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
210000004884 grey matter Anatomy 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
230000003862 health status Effects 0.000 description 1
235000012907 honey Nutrition 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
229940096397 interleukin-8 Drugs 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000000463 material Substances 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
108020004084 membrane receptors Proteins 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
108091052785 miR-1b stem-loop Proteins 0.000 description 1
239000000203 mixture Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
210000005012 myelin Anatomy 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000004248 oligodendroglia Anatomy 0.000 description 1
210000001328 optic nerve Anatomy 0.000 description 1
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
210000002975 pon Anatomy 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 1
235000007715 potassium iodide Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000012545 processing Methods 0.000 description 1
208000037821 progressive disease Diseases 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000002784 sclerotic effect Effects 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000013049 sediment Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000004885 white matter Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

UA2003044038A 2000-10-04 2001-03-10 Use of mutants of cc chemokines for treatment of multiple sclerosis UA77950C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP00121665		2000-10-04
PCT/EP2001/011428 WO2002028419A2 (en)	2000-10-04	2001-10-03	Chemokine mutants in the treatment of multiple sclerosis

Publications (1)

Publication Number	Publication Date
UA77950C2 true UA77950C2 (en)	2007-02-15

Family

ID=8170011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003044038A UA77950C2 (en)	2000-10-04	2001-03-10	Use of mutants of cc chemokines for treatment of multiple sclerosis

Country Status (30)

Country	Link
US (1)	US7402303B2 (sr)
EP (1)	EP1326628B1 (sr)
JP (1)	JP3908165B2 (sr)
KR (1)	KR100837898B1 (sr)
CN (1)	CN1285381C (sr)
AR (1)	AR030854A1 (sr)
AT (1)	ATE265222T1 (sr)
AU (2)	AU1591902A (sr)
BG (1)	BG66137B1 (sr)
BR (1)	BR0114407A (sr)
CA (1)	CA2423616C (sr)
CZ (1)	CZ303409B6 (sr)
DE (1)	DE60103078T2 (sr)
DK (1)	DK1326628T3 (sr)
EA (1)	EA006137B1 (sr)
EE (1)	EE05174B1 (sr)
ES (1)	ES2217199T3 (sr)
HR (1)	HRP20030215B1 (sr)
HU (1)	HUP0302194A3 (sr)
IL (2)	IL155178A0 (sr)
MX (1)	MXPA03003008A (sr)
NO (1)	NO330278B1 (sr)
PL (1)	PL204231B1 (sr)
PT (1)	PT1326628E (sr)
RS (1)	RS50738B (sr)
SI (1)	SI1326628T1 (sr)
SK (1)	SK287523B6 (sr)
UA (1)	UA77950C2 (sr)
WO (1)	WO2002028419A2 (sr)
ZA (1)	ZA200302315B (sr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7553483B2 (en)	2001-12-17	2009-06-30	Merck Serono Sa	Chemokine mutants acting as chemokine antagonists
JP2005529099A (ja) *	2002-04-04	2005-09-29	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	改善された経口生物学的利用能を有するケモカイン変異体
CA2507008A1 (en) *	2002-12-23	2004-07-29	Applied Research Systems Ars Holding N.V.	Use of cc-chemokine mutants against liver diseases
US20090022657A1 (en) *	2003-10-22	2009-01-22	Applied Research Systems Ars Holding N.V.	Novel CXCL8 antagonists
AT412785B (de) *	2003-12-04	2005-07-25	Kungl Andreas J Dr	Gag-bindungsproteine
ATE322506T1 (de) *	2004-01-19	2006-04-15	Ares Trading Sa	Verfahren zur reinigung von in bakterien exprimierten proteinen
GB0412400D0 (en) *	2004-06-03	2004-07-07	Univ Newcastle	Treatment of inflammatory conditions
EP2218748B1 (en) *	2005-09-03	2012-10-10	Samsung SDI Co., Ltd.	Polybenzoxazine-based compound, electrolyte membrane including the same, and fuel cell employing the electrolyte membrane
GB0614755D0 (en)	2006-07-25	2006-09-06	Univ Geneve	Cytokine derivatives
EP2185719B1 (en)	2007-08-02	2013-11-13	NovImmune SA	Anti-rantes antibodies and methods of use thereof
WO2011097640A1 (en) *	2010-02-08	2011-08-11	The Trustees Of The University Of Pennsylvania	Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same
EP3813869B1 (en)	2018-05-28	2023-10-18	Université de Genève	Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation
WO2022093857A1 (en) *	2020-10-26	2022-05-05	City Of Hope	Oncolytic virus compositions and methods for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5739103A (en) *	1993-11-12	1998-04-14	Dana-Farber Cancer Institute	Chemokine N-terminal deletion mutations
WO1998006751A1 (en) *	1996-08-16	1998-02-19	Research Corporation Technologies, Inc.	Mcp-3, rantes and mip-1alpha receptor antagonists
EP0906954A1 (en) *	1997-09-29	1999-04-07	Applied Research Systems ARS Holding N.V.	Amino-terminal truncated c-c chemokines as chemokine antagonist
CA2316447C (en) *	1997-12-23	2009-07-28	Fondazione Centro San Raffaele Del Monte Tabor	Rantes mutants and therapeutic applications thereof
AU2740900A (en) *	1999-01-29	2000-08-18	Millennium Pharmaceuticals, Inc.	Method of treating demyelinating inflammatory disease using ccr1 antagonists

2001
- 2001-03-10 UA UA2003044038A patent/UA77950C2/uk unknown
- 2001-10-03 KR KR1020037004599A patent/KR100837898B1/ko not_active Expired - Fee Related
- 2001-10-03 RS YUP-257/03A patent/RS50738B/sr unknown
- 2001-10-03 CN CNB018199178A patent/CN1285381C/zh not_active Expired - Fee Related
- 2001-10-03 ZA ZA200302315A patent/ZA200302315B/en unknown
- 2001-10-03 BR BR0114407-3A patent/BR0114407A/pt not_active IP Right Cessation
- 2001-10-03 PL PL362350A patent/PL204231B1/pl not_active IP Right Cessation
- 2001-10-03 DE DE60103078T patent/DE60103078T2/de not_active Expired - Lifetime
- 2001-10-03 EA EA200300439A patent/EA006137B1/ru not_active IP Right Cessation
- 2001-10-03 CZ CZ20030947A patent/CZ303409B6/cs not_active IP Right Cessation
- 2001-10-03 HR HR20030215A patent/HRP20030215B1/xx not_active IP Right Cessation
- 2001-10-03 ES ES01986265T patent/ES2217199T3/es not_active Expired - Lifetime
- 2001-10-03 PT PT01986265T patent/PT1326628E/pt unknown
- 2001-10-03 EE EEP200300139A patent/EE05174B1/xx not_active IP Right Cessation
- 2001-10-03 AU AU1591902A patent/AU1591902A/xx active Pending
- 2001-10-03 DK DK01986265T patent/DK1326628T3/da active
- 2001-10-03 AT AT01986265T patent/ATE265222T1/de active
- 2001-10-03 CA CA2423616A patent/CA2423616C/en not_active Expired - Fee Related
- 2001-10-03 US US10/398,457 patent/US7402303B2/en not_active Expired - Fee Related
- 2001-10-03 SI SI200130130T patent/SI1326628T1/xx unknown
- 2001-10-03 AU AU2002215919A patent/AU2002215919B2/en not_active Ceased
- 2001-10-03 SK SK406-2003A patent/SK287523B6/sk not_active IP Right Cessation
- 2001-10-03 JP JP2002532243A patent/JP3908165B2/ja not_active Expired - Fee Related
- 2001-10-03 HU HU0302194A patent/HUP0302194A3/hu unknown
- 2001-10-03 MX MXPA03003008A patent/MXPA03003008A/es active IP Right Grant
- 2001-10-03 EP EP01986265A patent/EP1326628B1/en not_active Expired - Lifetime
- 2001-10-03 IL IL15517801A patent/IL155178A0/xx unknown
- 2001-10-03 WO PCT/EP2001/011428 patent/WO2002028419A2/en not_active Ceased
- 2001-10-04 AR ARP010104684A patent/AR030854A1/es unknown
2003
- 2003-03-28 BG BG107685A patent/BG66137B1/bg unknown
- 2003-04-01 IL IL155178A patent/IL155178A/en not_active IP Right Cessation
- 2003-04-03 NO NO20031525A patent/NO330278B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HRP20030215A2 (en)	2005-02-28
EA200300439A1 (ru)	2003-08-28
PT1326628E (pt)	2004-09-30
MXPA03003008A (es)	2003-07-14
WO2002028419A2 (en)	2002-04-11
CA2423616A1 (en)	2002-04-11
DK1326628T3 (da)	2004-08-09
EE05174B1 (et)	2009-06-15
NO330278B1 (no)	2011-03-21
HUP0302194A3 (en)	2005-12-28
DE60103078T2 (de)	2005-04-07
SI1326628T1 (en)	2004-10-31
CN1477969A (zh)	2004-02-25
IL155178A0 (en)	2003-11-23
AU1591902A (en)	2002-04-15
BG66137B1 (bg)	2011-07-29
AR030854A1 (es)	2003-09-03
ES2217199T3 (es)	2004-11-01
NO20031525D0 (no)	2003-04-03
HK1062811A1 (en)	2004-11-26
BR0114407A (pt)	2003-07-29
HUP0302194A2 (hu)	2003-10-28
EP1326628B1 (en)	2004-04-28
PL204231B1 (pl)	2009-12-31
SK4062003A3 (en)	2003-08-05
RS50738B (sr)	2010-08-31
WO2002028419A3 (en)	2002-06-13
NO20031525L (no)	2003-04-03
BG107685A (bg)	2003-11-28
KR100837898B1 (ko)	2008-06-13
KR20030034238A (ko)	2003-05-01
EP1326628A2 (en)	2003-07-16
CZ2003947A3 (cs)	2003-11-12
CZ303409B6 (cs)	2012-09-05
CN1285381C (zh)	2006-11-22
IL155178A (en)	2009-07-20
ATE265222T1 (de)	2004-05-15
US7402303B2 (en)	2008-07-22
DE60103078D1 (de)	2004-06-03
EE200300139A (et)	2003-06-16
CA2423616C (en)	2010-03-16
JP3908165B2 (ja)	2007-04-25
SK287523B6 (sk)	2011-01-04
PL362350A1 (en)	2004-10-18
HRP20030215B1 (en)	2011-09-30
ZA200302315B (en)	2004-03-25
US20040101509A1 (en)	2004-05-27
YU25703A (sh)	2006-05-25
EA006137B1 (ru)	2005-10-27
JP2004510426A (ja)	2004-04-08
AU2002215919B2 (en)	2005-11-24

Publication	Publication Date	Title
RU2411042C2 (ru)	2011-02-10	Композиции и способы для лечения острого респираторного синдрома (sars)
US8022176B2 (en)	2011-09-20	FAS peptide mimetics and uses thereof
CN110092837B (zh)	2024-01-02	Uti融合蛋白
JPH04500970A (ja)	1992-02-20	マクロファージ由来炎症メディエーター　（ｍｉｐ―２）
JP2007510403A (ja)	2007-04-26	ケモカイン変異体の治療への使用
CA3091139A1 (en)	2019-08-29	Dosing for treatment with il-22 fc fusion proteins
JP3908165B2 (ja)	2007-04-25	多発性硬化症の治療におけるケモカイン変異体
EP2358738A2 (en)	2011-08-24	Modulators of the cx3cr1 receptor and therapeutic uses thereof
US20230303646A1 (en)	2023-09-28	Analogs of human fibroblast growth factors
AU2002215919A1 (en)	2002-06-27	Chemokine mutants in the treatment of multiple sclerosis
AU4904500A (en)	2000-12-18	Chemokine receptor ccr3 antagonists
KR100870296B1 (ko)	2008-11-25	융합 단백질
US20110028399A1 (en)	2011-02-03	Citrullinated cytokines
CA2688543C (en)	2017-08-22	Vegf-d mutants and their use
US20070161550A1 (en)	2007-07-12	Antiviral compositions which inhibit paramyxovirus infection
ES2355260T3 (es)	2011-03-24	Antagonistas de cadherina r selectivos y procedimientos.